MedTrace Logo

The Use of Kineret (Anakinra) in the Treatment of Familial Cold Urticaria

NCT00214851 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2022-11-08

No results posted yet for this study

Summary

An open labelled trial of Kineret (anakinra) induction therapy (100mg./day) in over a four week period in the treatment of Familial Cold Urticaria.

Familial Cold Urticaria (FCU) is a rare autosomal dominant condition manifesting symptoms triggered by exposure to cold and variable in expression. Currently there is no standard reliable agent available for the treatment of patients with FCU.This study will evaluate the efficacy of Kineret (anakinra), an interleukin 1 receptor antagonist in induction and maintenance therapy in patients with FCU.

Conditions

  • Familial Cold Urticaria

Interventions

DRUG

Kineret (anakinra)

Kineret (anakinra 100 mg. s/c daily x 4 weeks

Sponsors & Collaborators

  • Atlantic Provinces Dermatology Association

    collaborator UNKNOWN

  • Nova Scotia Health Authority

    lead OTHER

Principal Investigators

  • Laura A. Finlayson MD FRCPC · Nova Scotia Health Authority

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-09-30
Primary Completion
2005-12-31
Completion
2005-12-31

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00214851 on ClinicalTrials.gov